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The objective of the present study was to determine the effects of the commercially available type 2 Porcine
Reproductive and Respiratory Syndrome Virus (PRRSV)-based modified live vaccine against type 1 and type 2 PRRSV
challenge in pregnant sows. Half of the sows in the study were vaccinated with a type 2 PRRSV-based vaccine 4
weeks prior to artificial insemination while the other half remained non-vaccinated. Sows were then challenged
intranasally with type 1 or type 2 PRRSV at 93 days of gestation. The sows which received the type 2 PRRSV-based
vaccine followed by type 2 PRRSV challenge had significantly higher neutralizing antibody titers against type 2
PRRSV than they did against type 1 PRRSV. These same sows had higher frequencies of IFN-γ-secreting cells when
stimulated with type 2 PRRSV compared to those stimulated with type 1 PRRSV. Subsequent virological evaluation
demonstrated that the type 2 PRRSV-based vaccine reduced the type 2 PRRSV load but not the type 1 PRRSV load
present in the blood of the sows. Additionally, vaccination of pregnant sows with the type 2 PRRSV-based vaccine
effectively reduced the level of type 2 PRRSV nucleic acids observed in fetal tissues from type 2 PRRSV-challenged
sows but did not reduce the level of type 1 PRRSV nucleic acid observed in fetal tissues from type 1 PRRSV-challenged
sows. This study demonstrates that the vaccination of pregnant sows with the type 2 PRRSV-based vaccine protects
against type 2 PRRSV challenge but does not protect against type 1 PRRSV challenge.Introduction
Porcine Reproductive and Respiratory Syndrome (PRRS)
Virus (PRRSV) is a widely disseminated and economic-
ally important swine virus that is known to cause repro-
ductive failure in pregnant sows and respiratory disease
in nursery and grower/finishing pigs [1]. In the early
1990s, all European PRRSV isolates were closely related
and all North American isolates were also closely re-
lated, however, the two groups were distant from one* Correspondence: swine@snu.ac.kr
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reproduction in any medium, provided the oranother [2-4]. Later, genetic analysis defined the two
main genotypes of PRRSV: type 1 (European-like) and
type 2 (North American-like) [3,5]. Type 1 and type 2
PRRSV differ significantly in terms of their clinical, gen-
etic, and antigenic aspects [6-8]. At the present time,
type 1 PRRSV is also found in both North American and
Asian countries [9-12].
The commercial modified live virus (MLV) vaccine
(Ingelvac® PRRS MLV, Boehringer Ingelheim Vetmedica
Inc., St. Joseph, MO, USA) based on type 2 PRRSV was
first licensed for worldwide use in 3 to 18-week-old pigs
in 1994 and in pregnant female breeding-stock pigs in
1996. This MLV vaccine has been used extensively by
swine producers to protect pigs against PRRSV infection. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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2 PRRSV-based vaccine against type 1 PRRSV is a major
issue because of the co-existence of type 1 and type 2
PRRSV in many Asian countries [10-12]. However, no
peer-reviewed studies have assessed the efficacy of the
type 2 PRRSV-based vaccine against type 1 and type 2
PRRSV in pregnant gilts. Therefore, the objective of this
study was to determine the effects of the type 2 PRRSV-
based vaccine against type 1 and type 2 PRRSV challenge
in pregnant sows, using clinical, immunological, viro-
logical, and pathological measures for evaluation.
Materials and methods
PRRSV inocula
Type 1 (SNUVR090485) and type 2 (SNUVR100059)
PRRSV were used as inocula. The SNUVR090485 virus was
isolated from lung samples from an aborted fetus in 2009
in the Kyounggi Province. The SNUVR100059 was isolated
from lymph node samples of an aborted fetus in 2009 in
the Chungcheung Province. The nucleotide sequence
homology in open reading frame (ORF) 5 between the
type 1 PRRSV (SNUVR090485, Genbank no. JN315686)
and the vaccine strain (Genbank no. AF535152) is
68% and between the type 2 PRRSV (SNUVR100059,
Genbank no. JX988620) and the vaccine strain is 84%.
Sequence homology was determined using BioEdit ver-
sion 7.0.0 (Ibis Biosciences, Carlsbad, CA, USA) [13].
Experimental design
Twenty-six seronegative sows (parity = 2) were pur-
chased from a PRRSV-free herd. All sows were moved
to a research facility, housed individually in separate
rooms, and randomly allocated into 6 groups: the vac-
cinated and type 1 PRRSV-challenged group (group 1,
n = 5), the vaccinated and type 2 PRRSV-challenged
group (group 2, n = 5), the non-vaccinated and type 1
PRRSV-challenged group (group 3, n = 5), the non-
vaccinated and type 2 PRRSV-challenged group (group
4, n = 5), the vaccinated and non-challenged group
(group 5, n = 3), and the negative control group which
was non-vaccinated and non-challenged (group 6,
n = 3) (Table 1).
The estrous cycles of all sows were synchronized as
previously described [14]. Sows in groups 1, 2, and 5
were intramuscularly vaccinated with a 2.0 mL dose of
the type 2-based PRRSV vaccine (Ingelvac® PRRS MLV,
Boehringer Ingelheim Vetmedica Inc.) 4 weeks prior to
artificial insemination, according to the manufacturer's
instructions. Sows from all 6 groups were inseminated
with 80 mL of extended semen every 24 h for 3 days.
The sows were then monitored for signs of estrus, and
any sows that recycled were re-inseminated at 24 h in-
tervals for 3 days. At approximately 5 and 8 weeks post
artificial insemination, pregnancy was confirmed withultrasonography. Sows were then allowed to gestate and
carry the pregnancy to term.
At 3 weeks antepartum (93 days of gestation), the vac-
cinated sows from group 1 and the non-vaccinated sows
from group 3 were inoculated intranasally with 6 mL of
tissue culture supernatant containing 1.0 × 104 tissue
culture infective dose of 50% (TCID50)/mL of type 1
PRRSV (SNUVR090485, 2nd passage in alveolar macro-
phages). The vaccinated sows from group 2 and the non-
vaccinated sows from group 4 were inoculated intranasally
with 6 mL of tissue culture supernatant containing 1.0 ×
104 TCID50/mL of type 2 PRRSV (SNUVR100059, 2
nd pas-
sage in MARC-145 cells). The vaccinated sows from group
5 and the negative control sows from group 6 were simi-
larly inoculated with uninfected cell culture supernatant.
Each inoculum was instilled over a period of 4–5 min into
both nostrils. The sows were housed in isolation facilities
and allowed to farrow naturally, under supervision. Blood
samples from each sow were collected by jugular
venipuncture at −28, −21, 0, 56, 93, 100, 107, and 114 days
of gestation.
All live-born piglets were humanely euthanized with
an intravenous overdose of pentobarbital for tissue col-
lection and evaluation. All expelled fetuses (mummified,
dead, and live-born) from all study groups were necrop-
sied and evaluated for gross lesions. Crown-to-rump
measurements were used to determine the approximate
gestational time of fetal death for the mummified and
dead fetuses [15]. This study was approved by the Seoul
National University Institutional Animal Care and Use
Committee.
Serology
The serum samples were tested using the commercially
available PRRSV ELISA (HerdCheck PRRS 2XR, IDEXX
Laboratories Inc., Westbrook, ME, USA). Serum virus
neutralization (SVN) tests were also performed using a
heterologous challenging type 1 or type 2 PRRSV. Serum
samples were heat-inactivated for 45 min at 56 °C before
testing. Each serum was then diluted using a twofold
serial dilution technique in RPMI-1640 (Sigma Aldrich
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10% FCS (Sigma), 20 mM L-glutamine (Cellgro, Herdon,
VA, USA), and an antibiotic–anti-mycotic mixture (Sigma
Aldrich Corporation) which consisted of 100 IU/mL peni-
cillin, 100 mg/mL streptomycin, 50 mg/mL gentamicin,
and 0.25 mg/mL amphotericin B (here-after, RPMI growth
medium). One hundred microliters of each diluted sample
was mixed with an equal volume of each virus at a rate of
1.0 × 103 TCID50/mL of both a heterologous challenging
type 1 and type 2 PRRSV. Mixtures were incubated for 1 h
at 37 °C and then each mixture was inoculated onto
MARC-145 cell mono-layers prepared in 96-well Plates
24 h earlier. Each sample was run in duplicate. After 1h in-
cubation at 37 °C, all inocula were removed and replaced
with 200 μL of RPMI growth medium. Thereafter, the cells
were incubated at 37 °C and monitored daily for cytopathic
effect (CPE). The titer of inoculated virus was verified by
the back titration of the inoculum. The presence of virus-
specific CPE in each well was recorded after incubating for
7 days. The presence of virus in wells without CPE was
further determined by immunofluorescence microscopy
using SDOW17-FITC conjugate (Rural Technologies Inc.,
Brookings, SD, USA) [16,17]. Serum samples were consi-
dered to be positive for PRRSV neutralizing antibodies
(NA) if the titer was greater than 2.0 (log2) [18].
Enzyme-linked immunospot (ELISPOT) assay
The numbers of PRRSV-specific interferon-γ-secreting
cells (IFN-γ-SC) were determined in peripheral blood
mononuclear cells (PBMC) at −28, −21, 0, 56, 93, 100,
107 and 114 days of gestation as previously described
[19,20] with some modifications. Briefly, 50 μL con-
taining 5 × 105 PBMC in RPMI 1640 medium that was
supplemented with 10% fetal bovine serum (HyClone
Laboratories, Inc., SelectScience, Bath, UK), 1 mM non-
essential amino acids (Invitrogen, Carlsbad, CA, USA),
1 mM sodium pyruvate, 5 mM 2-mercaptoethanol, 50
000 IU/l penicillin l, and 50 mg/L streptomycin were
seeded into plates that were precoated overnight at 4 °C
with anti-porcine IFN-γ monoclonal antibody (10 μg/mL,
MABTECH, Mariemont, OH, USA). The plates were stim-
ulated by addition of either a heterologous challenging type
1 or type 2 PRRSV solution in RPMI 1640 medium for 20 h
at 37 °C in a 5% humidified CO2 atmosphere. The linear re-
sponse was tested between 0.1 and 1 MOI (multiplicity of
infection). Phytohemagglutinin (10 μg/mL, Roche Diagnos-
tics GmbH, Mannheim, Germany) and culture medium
were used as positive and negative controls, respectively.
Next, the wells were washed five times with PBS (200 μL
per well). Thereafter, the procedure was conducted accord-
ing to the manufacturer’s instructions using the commercial
ELISPOT Assay Kit (MABTECH). The spots on the mem-
branes were read by an automated ELISPOT Reader (AID
ELISPOT Reader, AID GmbH, Strassberg, Germany). Theresults were expressed as the numbers of IFN-γ-SC per mil-
lion PBMC.
Quantification of PRRSV RNA in blood
RNA extractions from the serum samples were per-
formed as previously described [21,22]. Real-time PCR
for type 1 and type 2 PRRSV, and vaccine strain were
used to quantify PRRSV genomic cDNA copy numbers
using RNA extraction from serum samples. The se-
quences of primers and probes in real-time PCR are
100% complementary to the sequences of the challenge
viruses (except 89.5% complementary for reverse primer
of type 2 PRRSV). Real-time PCR was considered posi-
tive if the cycle threshold (CT) level was obtained at ≤
45 cycles.
To construct a standard curve, real-time PCR was per-
formed in quadruplicate in two different assays: (i) 10-
fold serial dilutions of the PRRSV plasmid were used as
the standard, with concentrations ranging from 1010 to
103 copies/mL and (ii) 10-fold serial dilutions of the
challenging type 1 and type 2 PRRSV cultured in alveolar
macrophages and MARC-145 cells, respectively, from 1.0 ×
106 TCID50/mL to 1.0 × 10
-1 TCID50/mL. The PRRSV plas-
mid was prepared as previously described [23]. Briefly, the
transcript cDNA product was cloned into the pCR2.1 plas-
mid (Invitrogen, Carlsbad, CA, USA). The recombinant
plasmid was purified using a plasmid Miniprep kit (Qiagen,
Valencia, CA, USA) according to the manufacturer’s in-
structions, and the concentration of the purified plasmid
was determined using a spectrophotometer.
Virus isolation and sequence analysis
PRRSV was isolated from live-born piglets and stillborn
fetuses as previously described [24]. The isolated PRRSV
from fetuses were further analyzed for the ORF5 se-
quence. Sequencing was performed on the purified RT-
PCR products of amplified ORF5 [24,25].
In situ hybridization
The probe for the type 1 and type 2 PRRSV was gener-
ated from challenging type 1 and type 2 PRRSV by PCR
[26]. In situ hybridization (ISH) for the detection of type
1 and type 2 PRRSV nucleic acid in fetal tissues was
performed and analyzed morphometrically as previously
described [26,27].
Statistical analysis
ANOVA with a post-hoc Tukey’s test was used to com-
pare the primary variables for single comparison (ELISA
and SVN test, IFN-γ-SC, and PRRSV RNA quantifica-
tion) among the sows in 4 groups (groups 1, 2, 3, and 4).
ANOVA with a post-hoc Tukey’s test was used to com-
pare the primary variables (ISH scores) across the litters




























Figure 1 Mean group anti-PRRSV IgG antibody response in
different treatment groups. Sows that received PRRSV vaccine
followed by type 1 PRRSV challenge (group 1, □); sows that received
PRRSV vaccine followed by type 2 PRRSV challenge (group 2, ■);
non-vaccinated sows challenged with type 1 PRRSV (group 3, ○);
non-vaccinated sows challenged with type 2 PRRSV (group 4, ●);
and sow that received PRRSV vaccine (group 5, △). Variation is
expressed as the standard deviation. *Significant (P < 0.05)
difference between group 1 and group 3. †Significant (P < 0.05)
difference between group 2 and group 4.
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tionship among viremia, and PRRSV-specific NA titers and
IFN-γ-SC. P < 0.05 indicated statistical significance.
Results
Pregnancy
Sows in groups 1, 3, and 4 farrowed between 102 and
109 days of gestation while sows in groups 2, 5, and 6
carried their pregnancies to term and farrowed between
114 and 115 days of gestation. The number of litters
from the sows in all 6 groups is summarized in Table 2.
Anti- PRRSV IgG antibodies in sows
The IgG antibody response in sows was measured using
a commercially available ELISA. The results from these
experiments are summarized in Figure 1. Anti-PRRSV
IgG antibodies were not detected in the serum samples
at −28 days of gestation (time to PRRSV vaccination) in
sows from any of the 6 groups but were detected in the
serum samples at days 0 (28 days post-vaccination), 56,
and 93 (time to PRRSV challenge) of gestation in sows
that received the PRRSV vaccine (groups 1, 2, and 5).
At days 100 and 107 of gestation, sows that received
the PRRSV vaccine followed by type 1 PRRSV challenge
(group 1) and type 2 PRRSV challenge (group 2) had
significantly higher anti-PRRSV IgG antibody levels (P <




n Average lengthb (cm) Length rangeb (cm)
1 (5) 106-109 Live-born 3 29.4 29.0-30.1
Stillborn 45 28.8 28.1-29.6
Mummified 1 14.1 13.4-16.3
2 (5) Term Live-born 49 30.5 30.1-32.4
Stillborn 2 29.2 29.0-29.4
Mummified - - -
3 (5) 102-107 Live-born 5 28.9 28.6-29.4
Stillborn 42 27.9 27.1-28.5
Mummified - - -
4 (5) 103-108 Live-born 7 27.9 27.6-29.1
Stillborn 41 27.3 27.1-27.7
Mummified - - -
5 (3) Term Live-born 26 31.3 30.8-32.1
Stillborn 1 29.5 29.5
Mummified - - -
6 (3) Term Live-born 29 31.6 30.3-32.1
Stillborn - - -
Mummified - - -
an, number of sows in group.
bEstimation of fetal death based on crown-to-rump length.
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spectively. At day 114 of gestation, the sows that had re-
ceived the PRRSV vaccine followed by the type 2 PRRSV
challenge (group 2) had significantly higher anti-PRRSV
IgG antibody levels (P < 0.05) than the non-vaccinated
sows in group 4 (Figure 1).PRRSV-specific neutralizing antibodies
Serum virus neutralization (SVN) tests were also per-
formed using both type 1 and type 2 PRRSV. The results
are summarized in Table 3. No type 1 or type 2 PRRSV-
specific NA titers were detected in sera from sows in 4
groups (groups 1, 2, 3, and 4) at −28, −21, 0, 56, and 93
days of gestation. After challenge with type 1 PRRSV,
sera from sows that had received type 2 PRRSV-based
vaccine followed by type 1 challenge (group 1) showed
similar neutralizing activity against type 1 and type 2
PRRSV at 100, 107, and 114 days of gestation. In con-
trast, sera from sows that had received the type 2
PRRSV-based vaccine followed by type 2 PRRSV chal-
lenge (group 2) showed significantly higher neutralizing
activity against type 2 PRRSV than that against type 1
PRRSV at 100 (P = 0.004), 107 (P = 0.001), and 114 (P =
0.001) days of gestation. Sera from non-vaccinated sows
that had been challenged with type 1 PRRSV (group 3)
showed similar neutralizing activity against type 1 and
type 2 PRRSV at 100, 107, and 114 days of gestation.
Sera from non-vaccinated sows that had been challenged
with type 2 PRRSV (group 4) showed significantly higher
neutralizing activity against type 2 PRRSV than against
type 1 PRRSV at 107 (P = 0.006) and 114 (P = 0.004) days
of gestation (Table 3). No type 1 and type 2 PRRSV-
specific NA titer was detected in the 2 control groups
that were not challenged with PRRSV (groups 5 and 6).Table 3 Serum viral neutralization test results using type 1 an
Against type 1 PRRSV
Days of gestation
Group 93 100 107 114
1 0/5* 0/5 2/5a 3/5
0.40 ± 0.79 1.73 ± 0.85 2.29 ± 0.41b 2.21 ± 0.1
2 0/5 0/5 0/5 1/5
0.25 ± 0.50 0.75 ± 0.50 1.29 ± 0.34 2.05 ± 0.07
3 0/5 0/5 2/5 3/5
- 1.15 ± 0.29 2.01 ± 0.02 2.19 ± 0.3
4 0/5 0/5 0/5 1/5
- 0.50 ± 0.58 1.15 ± 0.29 2.02 ± 0.0
aNumber of positive/negative sows.
bMean titers (log2) and standard deviation. Mean titers have been calculated as the
cRepeated value of single positive sample.
*Statistical difference (P < 0.05) for neutralizing activity against type 1 PRRSV and agPRRSV-specific interferon- γ-secreting cells
To further access the immunological response to PRRSV
challenge, PRRSV-specific IFN-γ-SC were measured. The
results are summarized in Figure 2. When PBMC were
stimulated with type 1 PRRSV, mean frequencies of type 1
PRRSV-specific IFN-γ-SC remained at basal levels (< 20
cells/106 PBMCs) in sows from 5 groups at −28, 0, 56, and
93 days of gestation. At later times, the frequency of type 1
PRRSV-specific IFN-γ-SC began to increase and reached an
average of 68.3 ± 19.1 cells/106 PBMC in sows having re-
ceived the type 2 PRRSV-based vaccine followed by type 1
PRRSV challenge (group 1) at 114 days of gestation (21 days
post challenge) and 53.8 ± 5.6 cells/106 PBMC in non-
vaccinated sows that had been challenged with type 1
PRRSV challenge (group 3; Figure 2A). Mean frequencies
of type 1 PRRSV-specific IFN-γ-SC remained at basal levels
(< 20 type 1 PRRSV-specific IFN-γ-SC/106 PBMC) in sows
from the 3 groups (groups 2, 4, and 5) at 100, 107, and 114
days of gestation.
When PBMC were stimulated with type 2 PRRSV,
mean frequencies of type 2 PRRSV-specific IFN-γ-SC
remained at basal levels (< 20 cells/106 PBMC) in sows
that had received the type 2 PRRSV-based vaccine
followed by type 1 PRRSV challenge (group 1) and by type
2 PRRSV challenge (group 2) at −28 and −21 days of gesta-
tion. At later time points, the frequency of type 2 PRRSV-
specific IFN-γ-SC/106 PBMC began to increase and
reached an average of 144.0 ± 30.6 cells/106 PBMC in sows
(groups 1, 2, and 5) at 56 days of gestation and decreased
an average of 85.3 ± 21.5 cells/106 PBMC in sows (groups
1, 2, and 5) at 93 days of gestation. Upon challenging with
PRRSV, while mean frequencies was further enhanced to
170.0 ± 25.4 cells/106 PBMC in sows (group 2), mean
frequencies did not show any significant change in sows
(group 1), and decreased gradually in non-challengedd type 2 PRRSV
Against type 2 PRRSV
Days of gestation
93 100 107 114
0/5 2/5 3/5 5/5
9 0.25 ± 0.50 2.11 ± 0.19 2.26 ± 0.49 2.75 ± 0.50
0/5 3/5 4/5 5/5
c 0.25 ± 0.50 2.34 ± 0.46* 3.51 ± 0.56* 3.75 ± 0.50*
0/5 1/5 1/5 2/5
4 - 2.02 ± 0.02 2.01 ± 0.01 2.11 ± 0.18
0/5 1/5 2/5 4/5
2 - 2.01 ± 0.01 2.00 ± 0.01* 2.97 ± 0.53*
arithmetic mean of positive sera only.







































































Figure 2 Frequency of type 1 (A) and type 2 (B) PRRSV-specific
IFN-γ-SC/106 PBMC. Sows that received PRRSV vaccine followed
by type 1 PRRSV challenge (group 1, □); sows that received PRRSV
vaccine followed by type 2 PRRSV challenge (group 2, ■); non-
vaccinated sows challenged with type 1 PRRSV (group 3, ○); non-
vaccinated sows challenged with type 2 PRRSV (group 4, ●); and
sows that received PRRSV vaccine (group 5, △).*Significant (P < 0.05)
difference between group 1 and group 3. †Significant (P < 0.05)
difference between group 2 and group 4.
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cies of type 2 PRRSV-specific IFN-γ-SC remained at
basal levels (< 20 type 2 PRRSV-specific IFN-γ-SC/106
PBMC) in sows that had been challenged with type 1
PRRSV (group 3) and type 2 PRRSV (group 4) at −28, −21,
0, 56, and 93 days of gestation. At later times, the fre-
quency of type 2 PRRSV-specific IFN-γ-SC/106 PBMC
began to increase and reached an average of 39.8 ± 19.1
cells/106 PBMC in sows (group 3) and 86.8 ± 16.5 cells/
106 PBMC (group 4) at 114 days of gestation (Figure 2B).
No type 1 and type 2 PRRSV-specific IFN-γ-SC was de-
tected in negative control sows (group 6) throughout the
experiment.
When equivalent series of IFN-γ-ELISPOT results
were compared between type 1 PRRSV stimulation ver-
sus type 2 PRRSV stimulation within the same groups,
some differences were seen (Figures 2A and B). Thus,stimulation with type 2 PRRSV produced higher fre-
quencies of IFN-γ-SC at 0, 56, 93 days of gestation com-
pared to the stimulation with type 1 PRRSV (95.5 ± 29.6
vs. 32.7 ± 9.4, 135.0 ± 14.6 vs. 17.5 ± 3.7, 78.5 ± 18.2 vs.
11.3 ± 7.1, respectively) in sows that had received the
type 2 PRRSV-based vaccine followed by type 1 PRRSV
challenge (group 1). After 14 days post challenge of type
1 PRRSV in group 1, there were no significantly different
frequencies of IFN-γ-SC between stimulation with type
1 and type 2 PRRSV. In contrast, stimulation with type 2
PRRSV produced higher frequencies of IFN-γ-SC at 0,
56, 93, 100, 107, 114 days of gestation compared to
stimulation with type 1 PRRSV (103.5 ± 33.5 vs. 28.0 ±
12.5, 139.8 ± 28.1 vs. 19.0 ± 11.4, 85.8 ± 17.1 vs. 13.0 ± 9.1,
121.7 ± 21.6 vs. 17.5 ± 4.2, 143.5 ± 13.4 vs. 24.0 ± 13.7,
170.0 ± 25.4 vs. 19.5 ± 11.1, respectively) in sows that had
received type 2 PRRSV-based vaccine followed by type 2
PRRSV challenge (group 2).
Quantification of PRRSV RNA in sow sera
The amount of PRRSV RNA in the sera of sows was
quantified using RT-PCR. Standard curves were con-
structed by plotting the ten-fold serial diluted plasmid
copy number logarithm against the measured CT values.
The linear correlation (R2) between the CT and the plas-
mid copy number logarithm were repeatedly greater
than 0.998 for the type 1 PRRSV and 0.997 for the type
2 PRRSV. The detection limit of the real-time PCR was
shown to be equivalent to 37 type 1 PRRSV copies (0.63
log10)/reaction and 41 type 2 PRRSV copies (0.62 log10)/
reaction.
Genomic copies of the vaccine strain were detected in
the serum of the vaccinated sows (groups 1, 2, and 5)
at −21 days of gestation. Thereafter, no vaccine strain
was detected in the serum from vaccinated sows
(Figure 3). Genomic copies of type 1 PRRSV were de-
tected in the serum of the sows that had received type 2
PRRSV-based vaccine followed by the type 1 PRRSV
challenge (group 1) and of the non-vaccinated sows
challenged with type 1 PRRSV (group 3) at days 100,
107, and 114 of gestation. However, there were no sig-
nificant differences between groups 1 (vaccinated) and 3
(non-vaccinated) in terms of their genomic copy number
of type 1 PRRSV at days 100, 107, and 114 of gestation
(Figure 3). Genomic copies of type 2 PRRSV were de-
tected in the serum of the sows that had received type 2
PRRSV-based vaccine followed by the type 2 PRRSV
challenge (group 2) and of the non-vaccinated sows that
had been challenged with the type 2 PRRSV (group 4) at
days 100, 107, and 114 of gestation. The non-vaccinated
sows in group 4 had significantly higher genomic copies
of type 2 PRRSV in their serum at gestational days 107
(P = 0.002) and 114 (P < 0.001) than did the vaccinated



























Figure 3 Mean values of the genomic copies of PRRSV RNA in
serum in different treatment groups. Sows that received PRRSV
vaccine followed by type 1 PRRSV challenge (group 1, □); sows that
received PRRSV vaccine followed by type 2 PRRSV challenge (group
2, ■); non-vaccinated sows challenged with type 1 PRRSV (group 3,
○); and non-vaccinated sows challenged with type 2 PRRSV (group
4, ●). *Significant (P < 0.05) difference between group 2 and group 4.
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throughout the experiment.
The number of genomic copies of type 2 PRRSV in
the blood correlated inversely with type 2 PRRSV-
specific NA titers (r2 = −0.998, P = 0.003) and type 2
PRRSV-specific IFN-γ-SC (r2 = −0.996, P = 0.050) in sows
that had received type 2 PRRSV-based PRRSV vaccine
followed by type 2 challenge (group 2).
Quantification of PRRSV RNA in stillborn fetuses and
live-born piglets
The amount of PRRSV RNA was also quantified in the
tissues of stillborn and live-born piglets. Litters from
non-vaccinated sows challenged with type 2 PRRSV
(group 4) had significantly higher scores for the mean
number of PRRSV-positive cells per unit area in several
organs (P < 0.05) than those from sows that received
type 2 PRRSV-based vaccine followed by type 2 PRRSV
challenge (group 2). No PRRSV or vaccine strain was
detected in several organs from sows in the 2 control
groups (groups 5 and 6) (Table 4).
In situ hybridization
In situ hybridization was also performed to detect type 1
and type 2 PRRSV genomes in the tissues from piglets.
As expected, type 1 PRRSV-positive cells were only de-
tected in the litters of piglets from sows in groups 1 and
3, while type 2 PRRSV-positive cells were only detected
in the litters from sows in groups 2 and 4 (Table 4). No
type 1 or type 2 PRRSV was detected in any litters from
sows in control groups 5 and 6. Regardless of their
PRRSV genotype, the positive cells generally had largeoval nuclei and abundant cytoplasm, which was consist-
ent with the morphology of macrophages in several or-
gans (Figure 4).
The score for the mean number of PRRSV-positive
cells per unit area of the organs examined did not differ
significantly between the litters of sows that had received
type 2 PRRSV vaccine followed by the type 1 PRRSV
challenge (group 1) and sows that had been challenged
with type 1 PRRSV (group 3) (Table 4). Litters from
non-vaccinated sows challenged with type 2 PRRSV
(group 4) had significantly higher scores for the mean
number of PRRSV-positive cells per unit area in several
organs (P < 0.05) than those from sows that received
type 2 PRRSV-based vaccine prior to type 2 PRRSV chal-
lenge (group 2) (Table 4).
Virus isolation and sequence analysis
Type 1 and type 2 PRRSV were isolated from several or-
gans from the live-born piglets and stillborn fetuses from
sows in groups 1, 2, 3, and 4 (Table 4). All isolated type
1 and type 2 PRRSV strains were confirmed by sequence
analysis to be of the same propagating virus as the chal-
lenge stock. No PRRSV was isolated from the serum of
sows in control groups 5 or 6. Vaccine strains were not
isolated from the live-born piglets or stillborn fetuses
from any sows used in this study.
Discussion
This study clearly demonstrates that the vaccination of
sows with the commercial type 2 PRRSV-based vaccine
protects pregnant sows against heterologous type 2
PRRSV challenge but not against type 1 PRRSV chal-
lenge. The statistical analysis shows that the vaccine
elicited a significant improvement in the number of live-
born pigs and a decrease in the number of mummified
fetuses in vaccinated sows challenged with the heterol-
ogous type 2 PRRSV (Table 2). Analysis of crown-to-
rump length is a critical parameter for the evaluation of
the effect of vaccination. Since crown-to-rump length of
stillborn fetuses was not significantly different between
sows vaccinated against type 2 PRRSV challenge and
negative control sows, these data further supported the
protection of type 2 PRRSV-based vaccine against type 2
PRRSV challenge.
Our results were in agreement with the previous find-
ings where the type 2 PRRSV-based vaccine provided
only partial protection against subsequent challenge of
heterologous virulent type 2 PRRSV in pregnant sows
[28,29]. Moreover, vaccination with type 1 PRRSV-based
vaccine reduced the level of viremia and clinical signs
after challenge with type 1 PRRSV, but barely reduced
the level of viremia and clinical signs after challenge
with the type 2 PRRSV challenge in preweaning pigs and
vice versa [30,31]. However, a recent cross-protection
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PRRSV-based vaccine provides partial protection against
challenge with a highly virulent type 2 PRRSV [32]. There-
fore, the extent of cross-protection is not solely related to
the genomic differences between the two genotypes.
Virological evaluation demonstrated that the type 2
PRRSV-based vaccine reduced the type 2 PRRSV load but
not the type 1 PRRSV load in the sow blood (Figure 3).
Because PRRSV was detected in the litters of pregnant
sows infected intranasally with PRRSV, PRRSV can infect
pregnant sows and can be transmitted from sow to fetus
through viremia and transplacental infection. Hence,
PRRSV in the blood plays an important role in the dissem-
ination of PRRSV to the fetuses of the pregnant sows.
Vaccination can decrease the PRRSV load in the blood of
pregnant sows and can subsequently decrease the risk of
maternal to fetal transmission through viremia. However,
sows that received a type 2 PRRSV-based vaccine followed
by a type 2 PRRSV challenge (group 2) were also viremic
similarly to any other group at early time points. Reduction
of viremia was not clearly seen until 107 days of gestation.Table 4 Virus isolation, and mean scores for PRRSV-positive c
positive numbers in litters from sows
Test Group n Lung LNa
PRRSV 1 48 41b 39
(real-time PCR) (1.3 ± 0.3)c (1.5 ± 0.4) (
2 51 6 5
(0.3 ± 0.1)* (0.4 ± 0.2)* (0
3 47 44 41
(1.5 ± 0.5) (1.8 ± 0.5) (
4 48 42 40
(1.4 ± 0.2) (1.5 ± 0.7) (
5 27 0 0
6 29 0 0
PRRSV 1 48 5.7 ± 1.9 13.5 ± 3.7
(ISH) 2 51 2.4 ± 0.9* 4.5 ± 1.1* 0
3 47 7.3 ± 1.7 16.7 ± 3.9
4 48 7.1 ± 2.2 14.8 ± 1.9
5 27 0 0
6 29 0 0
PRRSV 1 48 31 33
(Isolation) 2 51 0 0
3 47 34 36
4 48 33 35
5 27 0 0
6 29 0 0
aLN, inguinal lymph node.
bNumber of positive fetuses.
cMean values of the genomic copies of PRRSV RNA in fetal tissues (log10).
*Significant (P < 0.05) difference between group 2 and group 4.Thus, late abortions may have been prevented by the re-
duction of viremia; however, this link is not as clear with
early abortions, since at day 100 all sows were equally
viremic. Further studies are needed to elucidate the protect-
ive role of the PRRSV vaccine at preventing early abortion
in sows that received a type 2 PRRSV-based vaccine
followed by a type 2 PRRSV challenge.
For the pathological evaluation, the detection of
PRRSV replication within fetal tissues is critical in order
to determine the efficacy of the PRRSV vaccines. In the
present study, the vaccination of pregnant sows with the
type 2 PRRSV-based vaccine effectively reduced the level
of type 2 PRRSV nucleic acids and cell death in the fetal
tissues of litters from vaccinated and type 1 PRRSV-
challenged sows. However, vaccination with the type 2
PRRSV-based vaccine does not reduce the level of type 1
PRRSV nucleic acid in the fetal tissues of litters from the
vaccinated and type 2 PRRSV-challenged sows.
Upon PRRSV challenge at 93 days of gestation (121 days
post vaccination), NA titers were detected in vaccinated-
challenged sows. Interestingly, when cross-neutralizationells by in situ hybridization (ISH) and real-time PCR-
Heart Tonsil Thymus Liver Spleen
31 40 43 18 30
0.4 ± 0.5) (1.4 ± 0.6) (2.9 ± 0.6) (0.3 ± 0.3) (1.1 ± 0.4)
4 4 7 0 4
.1 ± 0.3)* (0.4 ± 0.3)* (0.5 ± 0.3)* 0* (0.2 ± 0.3)*
32 42 44 21 33
0.5 ± 0.4) (1.5 ± 0.6) (3.2 ± 0.7) (0.3 ± 0.1) (1.0 ± 0.5)
28 39 45 19 35
0.2 ± 0.2) (1.1 ± 0.3) (2.8 ± 0.4) (0.3 ± 0.3) (0.9 ± 0.4)
0 0 0 0 0
0 0 0 0 0
4.0 ± 0.9 13.1 ± 3.5 31.5 ± 6.9 2.4 ± 0.5 13.7 ± 2.3
.4 ± 0.5* 4.5 ± 1.2* 6.5 ± 2.4* 0* 1.6 ± 0.7*
3.4 ± 1.2 15.2 ± 2.9 40.8 ± 4.8 1.9 ± 0.8 13.9 ± 2.4
2.6 ± 1.3 15.0 ± 3.4 39.9 ± 5.1 1.8 ± 0.7 13.5 ± 2.6
0 0 0 0 0
0 0 0 0 0
20 30 34 11 23
0 0 0 0 0
21 29 37 14 27
20 26 35 12 27
0 0 0 0 0
0 0 0 0 0
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were significantly higher than the NA titers against type 1
PRRSV in the sera of sows that had received a type 2
PRRSV-based vaccine and a subsequent type 2 PRRSV chal-
lenge. Our results provide indirect evidence that the re-
activity is not the same for type 1 PRRSV antibodies against
type 2 PRRSV as for type 2 PRRSV antibodies against type
1 PRRSV. These observations are further supported by pre-
vious studies in which the inoculation with different PRRSV
strains resulted in varying levels of NA titers against the
PRRSV strains by cross-neutralization assays [33,34]. In
addition, homologous NA plays an important role in pro-
tection against experimental challenge and protection is
NA titers dependent [35,36]. Although there was a correl-
ation between NA titers and PRRSV viremia in vaccinatedFigure 4 In situ hybridization for the detection of PRRSV nucleic acid
PRRSV vaccine followed by type 1 PRRSV challenge (group 1, A); sows that
B); sows challenged with type 1 PRRSV (group 3, C); sows challenged withand challenged pigs, its precise role in the clearance of
viremia is uncertain because the NA levels were low in the
vaccinated and vaccinated-challenged sows throughout the
experiment. However, this study was not evaluating protec-
tion conferred by the vaccine by measuring viability not
only at birth but also at weaning, as has often been done by
previous publications using a reproductive failure model
[35,37]. Further studies are needed to determine the pro-
tective role of NA in newborn piglets from vaccinated and
challenged sows during the postnatal period.
Despite the low NA levels in response to PRRSV vac-
cination [38], the sows that received the type 2 PRRSV-
based vaccine followed by a type 2 PRRSV challenge still
efficiently cleared type 2 PRRSV in the blood. Presum-
ably this was at least partially dependent on cell-in the thymuses of the litters. The results are the sows that received
received PRRSV vaccine followed by type 2 PRRSV challenge (group 2,
type 2 PRRSV (group 4, D).
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IFN-γ is known to inhibit PRRSV replication [39,40].
The sows that received a type 2 PRRSV-based vaccine had
significantly higher frequencies of type 2 PRRSV-specific
IFN-γ-SC than frequencies of type 1 PRRSV-specific IFN-γ-
SC. The frequency of type 2 PRRSV-specific IFN-γ-SC was
approximately 75 PRRSV-specific IFN-γ-SC/106 PBMC at
the day of challenge. The vaccinated sows that did not de-
velop viremia had 45 PRRSV-specific IFN-γ-SC/106 PBMC
at the days of challenge [41]. Therefore, the 75 PRRSV-
specific IFN-γ-SC/106 PBMC were sufficient to reduce or
prevent type 2 PRRSV viremia after challenge with the viru-
lent type 2 PRRSV in sows that had received a type 2
PRRSV-based vaccine. Our results are further supported by
previous studies in which infections with different PRRSV
strains led to different PRRSV-specific IFN-γ-SC outcomes,
resulting in different degrees of heterologous protection
[33,42]. In addition, there is a strong correlation between
cell-mediated immunity, as measured by IFN-γ-SC, and
protection against reproductive failure in sows [43]. A posi-
tive correlation between type 2 PRRSV-specific IFN-γ-SC
and type 2 PRRSV viremia was found in sows that received
a type 2 PRRSV-based vaccine followed by a type 2 PRRSV
challenge. These results strongly suggest that PRRSV-
specific IFN-γ-SC is likely the main factor in the protection
of pregnant gilts against PRRSV. Therefore, differences in
the induction of PRRSV-specific IFN-γ-SC by type 2
PRRSV-based vaccine against challenge by type 1 and type
2 PRRSV may contribute to different protective outcomes.
Alternatively, it cannot be ruled out that levels of protection
in vaccinated sows may be directly due to using a different
challenge strain (type 1 vs. type 2 virus) regardless of differ-
ent frequency of PRRSV-specific IFN-γ-SC.
The vaccine company claims that the duration of im-
munity is throughout the gestation periods or at least
4 months post-vaccination [44]. Since vaccinated sows
were challenged with PRRSV at 3 weeks antepartum,
antigenic differences rather than duration of immunity
could be a major factor that influenced the outcome.
The results of this study indicate that sows that had re-
ceived type 2 PRRSV-based vaccine differ in their re-
sponse to PRRSV-specific neutralization and IFN-γ-SC
against different challenging type 1 and type 2 PRRSV
strains. Low efficiency of the type 2 PRRSV-based vac-
cine against type 1 PRRSV is most likely due to the anti-
genic differences between the vaccine and the challenge
virus.
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